Health Care
featured
Does this job make me look fat? A Gallup-Healthways survey takes a look at which jobs have high rates of obesity. And it's bad news for bus drivers.
» Read MoreMore
-
SANTA CLARA, Calif.-- Drug developer XenoPort said Friday that its treatment for restless leg syndrome, Horizant, will likely be available to U.S. patients in early June. Last month XenoPort Inc. said that there was a shortage of Horizant, with patients telling them that they were unable to fill prescriptions.
-
NEW YORK-- Shares of Oncothyreon Inc. fell Thursday after the drug developer announced new clinical trial data about an experimental lung cancer treatment that failed to improve overall survival rate. THE SPARK: Oncothyreon said that it identified some patients who appeared to live longer after treatment with Stimuvax.
-
Does this job make me look fat? A Gallup-Healthways survey takes a look at which jobs have high rates of obesity. And it's bad news for bus drivers.
-
CNBC's Julia Boorstin reports on companies that are looking to increase efficiency and implement simplicity in medical care. And, Grant Verstandig, Audax Health founder and CEO, discusses how his digital health care startup encourages consumers to make healthier lifestyle choices.
-
This marks the first companion diagnostic that detects epidermal growth factor receptor gene mutations to be approved by the U.S. Food and Drug Administration, the agency said.
-
The number of women choosing to have preventive mastectomies has risen by almost 50 percent in recent years, and surveys show they are happy with the decision.
-
LAKE FOREST, Ill.-- Drug and medical device maker Hospira Inc. said Tuesday that Dr.
-
The FDA in January asked zolpidem manufacturers, including NovaDel Pharma Inc and Swedish drugmaker Meda, to reduce recommended dosages on the drugs' labels. The FDA recommended doses of 5 mg for women and either 5 mg or 10 mg for men for immediate-release zolpidem products such as Sanofi's Ambien.
-
BOTHELL, Wash.-- Drug developer Seattle Genetics Inc. said Tuesday the Food and Drug Administration has accepted its application to market the lymphatic cancer treatment Adcetris for some additional uses. Seattle Genetics expects the FDA to make a decision by Sept. 14.
-
MIAMI-- Hospitals nationwide could lose half a billion dollars in federal funding for uninsured patients next year under the national health overhaul _ a loss that will hit especially hard in states that decided against expanding Medicaid coverage.
-
NEW YORK-- PDI Inc., which provides sales and marketing services to the biopharmaceutical industry, said Monday that it turned a profit in the first quarter. Net income was $2.1 million, or 14 cents per share. The company had a loss of $272,000, or 2 cents per share, a year ago.
-
*Ranbaxy says money set aside sufficient to cover costs. May 13- Indian generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice.
-
DUBLIN, May 13- Irish drugmaker Elan Corporation has agreed a $1 billion royalties deal that could soothe concerns about its potentially risky acquisition strategy and fend off a takeover bid from Royalty Pharma.
-
Under President Barack Obama's health care law, where you live could make a huge difference in what you'll pay for medications.
-
May 10- The U.S. Food and Drug Administration has approved a new drug to treat chronic obstructive pulmonary disease, a condition often associated with smoking that can include emphysema, chronic bronchitis, or both. The drug, Breo, is an inhaled treatment made by British drugmaker GlaxoSmithKline Plc and Theravance Inc of the United States.
-
The maker of the da Vinci surgical robot has flagged a potential issue, reports CNBC's Herb Greenberg.
-
NEW YORK-- New York City has won nearly $70 million from 44 pharmaceutical companies in a Medicaid fraud lawsuit over the pricing of prescription drugs. The New York City Law Department said Thursday that the city has already been paid about $60 million with the last settlements being processed.
-
Patent expirations on big-name drugs has resulted in modestly less spending on medicines in the U.S. for the first time in at least 55 years, a report showed Thursday.
-
CNBC's Rick Santelli maps out the problems he sees with the Patient Protection and Affordable Care Act.
-
.160x105.jpg?v=1368113691 "Execs' Cushy Health Insurance May Trigger Fines")
Under Obamacare, employers offering more generous benefits to highly paid workers could face fines of $100 a day for every worker who doesn't get the perks, up to $500,000.